Skip to main content

Advertisement

SpringerLink
Log in

Multimorbidity and the Etiology of Schizophrenia

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

A global study of multimorbidity in schizophrenia, especially of the association with physical conditions, might offer much needed etiological insights.

Recent Findings

Our review suggests that life-style factors and medication related to schizophrenia are only part of the explanation of the increase in risk for cardiovascular, metabolic, pulmonary disorders, and some cancers. Positive associations with autoimmune disorders (with the exception of rheumatoid arthritis) and epilepsy are promising avenues of research but to date have not been fully exploited. The same holds for the negative comorbidity seen for rheumatoid arthritis and some cancers (e.g., prostate).

Summary

As a whole, our review suggests that most of the explored conditions have a different prevalence in schizophrenia than in the general population. Several hypotheses emerged from this review such as the role of immune and genetic factors, of sex hormones, and of more general variability factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357–63.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Caron C, Rutter M. Comorbidity in child psychopathology: concepts, issues and research strategies. J Child Psychol Psychiatry. 1991;32:1063–80.

    Article  CAS  PubMed  Google Scholar 

  3. Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry Allied Disciplines. 1999;40:57–87.

    Article  CAS  Google Scholar 

  4. Lilienfeld SO, Waldman ID, Israel AC. A critical examination of the use of the term and concept of comorbidity in psychopathology research. Clin Psychol Sci Pract. 1994;1:71–83.

    Article  Google Scholar 

  5. •• Wetterling T. Pathogenesis of multimorbidity—what is known? Z Gerontol Geriatr. 2021;54:590–6. Interesting article describing different putative mechanisms that might explain multimorbidity.

    Article  PubMed  Google Scholar 

  6. Font H, Roelandt J-L, Behal H, Geoffroy P-A, Pignon B, Amad A, et al. Prevalence and predictors of no lifetime utilization of mental health treatment among people with mental disorders in France: findings from the ‘Mental Health in General Population’ (MHGP) survey. Soc Psychiatry Psychiatr Epidemiol. 2018;53:567–76.

    Article  PubMed  Google Scholar 

  7. Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47:1549–56.

    Article  PubMed  Google Scholar 

  8. • Kowal C, Peyre H, Amad A, Pelissolo A, Leboyer M, Schürhoff F, et al. Psychotic, mood, and anxiety disorders and venous thromboembolism: a systematic review and meta-analysis. Psychosom Med. 2020;82:838–49. This systematic review and meta-analysis of the association between venous thromboembolism and psychiatric disorders revealed that psychotic disorders increased the risk of pulmonary embolism, deep veinous thrombosis and fatal issues.

    Article  PubMed  Google Scholar 

  9. •• Ali S, Santomauro D, Ferrari AJ, Charlson F. Excess mortality in severe mental disorders: a systematic review and meta-regression. J Psychiatr Res. 2022;149:97–105. The most recent estimation, based on meta-analytical data, of the excess mortality from cardiovascular and diabetes in subjects with schizophrenia.

    Article  PubMed  Google Scholar 

  10. Ali S, Santomauro D, Ferrari AJ, Charlson F. Schizophrenia as a risk factor for cardiovascular and metabolic health outcomes: a comparative risk assessment. Epidemiol Psychiatr Sci. 2023;32:e8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Moran P, Stewart R, Brugha T, Bebbington P, Bhugra D, Jenkins R, et al. Personality disorder and cardiovascular disease: results from a national household survey. J Clin Psychiatry. 2007;68:69–74.

    Article  PubMed  Google Scholar 

  12. Quirk SE, El-Gabalawy R, Brennan SL, Bolton JM, Sareen J, Berk M, et al. Personality disorders and physical comorbidities in adults from the United States: data from the National Epidemiologic Survey on Alcohol and Related Conditions. Soc Psychiatry Psychiatr Epidemiol. 2015;50:807–20.

    Article  PubMed  Google Scholar 

  13. Mothi SS, Tandon N, Padmanabhan J, Mathew IT, Clementz B, Tamminga C, et al. Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders. Schizophr Res. 2015;165:103–7.

    Article  PubMed  PubMed Central  Google Scholar 

  14. • Suetani S, Honarparvar F, Siskind D, Hindley G, Veronese N, Vancampfort D, et al. Increased rates of respiratory disease in schizophrenia: a systematic review and meta-analysis including 619,214 individuals with schizophrenia and 52,159,551 controls. Schizophr Res. 2021;237:131–40. Recent meta-analysis of the association between schizophrenia and respiratory diseases (asthma, COPD, pneumonia).

    Article  PubMed  Google Scholar 

  15. Jaén-Moreno MJ, Rico-Villademoros F, Ruiz-Rull C, Laguna-Muñoz D, Del Pozo GI, Sarramea F. A systematic review on the association between schizophrenia and bipolar disorder with chronic obstructive pulmonary disease. COPD. 2023;20:31–43.

    Article  PubMed  Google Scholar 

  16. Mirabelli MC, Beavers SF, Chatterjee AB, Moorman JE. Age at asthma onset and subsequent asthma outcomes among adults with active asthma. Respir Med. 2013;107:1829–36.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pedersen MS, Benros ME, Agerbo E, Børglum AD, Mortensen PB. Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. Schizophr Res. 2012;138:58–62.

    Article  PubMed  Google Scholar 

  18. Wang WC, Lu ML, Chen VCH, Ng MH, Huang KY, Hsieh MH, et al. Asthma, corticosteroid use and schizophrenia: a nationwide population-based study in Taiwan. PLOS ONE. 2017;12:e0173063.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wu Q, Dalman C, Karlsson H, Lewis G, Osborn DPJ, Gardner R, et al. Childhood and parental asthma, future risk of bipolar disorder and schizophrenia spectrum disorders: a population-based cohort study. Schizophr Bull. 2019;45:360–8.

    Article  PubMed  Google Scholar 

  20. Judd LL, Schettler PJ, Brown ES, Wolkowitz OM, Sternberg EM, Bender BG, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. AJP. 2014;171:1045–51.

    Article  Google Scholar 

  21. Broberg BV, Sommer IE, Benros ME, Glenthøj BY, Gasse C, Köhler-Forsberg O. Glucocorticoids and the risk of schizophrenia spectrum disorder in childhood and adolescence – a Danish nationwide study. Schizophr Res. 2018;199:116–22.

    Article  PubMed  Google Scholar 

  22. Stevens JR. Schizophrenia and multiple sclerosis. Schizophr Bull. 1988;14:231–41.

    Article  CAS  PubMed  Google Scholar 

  23. Arneth BM. Multiple sclerosis and schizophrenia. Int J Mol Sci. 2017;18:1760.

    Article  PubMed  PubMed Central  Google Scholar 

  24. • Cao Y, Ji S, Chen Y, Zhang X, Ding G, Tang F. Association between autoimmune diseases of the nervous system and schizophrenia: a systematic review and meta-analysis of cohort studies. Compr Psychiatry. 2023;122:152370. Recent meta-analysis on the association between autoimmune nervous disorders (more notably multiple sclerosis) and schizophrenia (complements an older meta-analysis ref. 64, Cullen et al. focusing on non-neurological autoimmune disorders).

    Article  PubMed  Google Scholar 

  25. Meier U-C, Ramagopalan SV, Goldacre MJ, Goldacre R. Risk of schizophrenia and bipolar disorder in patients with multiple sclerosis: record-linkage studies. Front Psychiatry [Internet]. 2020 [cited 2023 Dec 21];11. Available from: https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00662.

  26. Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR. The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry. 2014;14:75.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand. 2004;110:207–20.

    Article  CAS  PubMed  Google Scholar 

  28. Qin P, Xu H, Laursen TM, Vestergaard M, Mortensen PB. Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study. BMJ. 2005;331:23.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Chang Y-T, Chen P-C, Tsai I-J, Sung F-C, Chin Z-N, Kuo H-T, et al. Bidirectional relation between schizophrenia and epilepsy: a population-based retrospective cohort study. Epilepsia. 2011;52:2036–42.

    Article  PubMed  Google Scholar 

  30. Wotton CJ, Goldacre MJ. Coexistence of schizophrenia and epilepsy: record-linkage studies. Epilepsia. 2012;53:e71–4.

    Article  PubMed  Google Scholar 

  31. Clarke MC, Tanskanen A, Huttunen MO, Clancy M, Cotter DR, Cannon M. Evidence for shared susceptibility to epilepsy and psychosis: a population-based family study. Biol Psychiat. 2012;71:836–9.

    Article  PubMed  Google Scholar 

  32. • Lindekilde N, Scheuer SH, Rutters F, Knudsen L, Lasgaard M, Rubin KH, et al. Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. Diabetologia. 2022;65:440–56. The most recent and complete analysis of the association between T2DM and psychiatric disorders (including psychosis/schizophrenia).

    Article  PubMed  Google Scholar 

  33. Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, Fernandez-Egea E, Miller B, Arroyo MB, et al. Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res. 2017;179:57–63.

    Article  PubMed  Google Scholar 

  34. Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Børglum AD, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry. 2017;174:686–94.

    Article  PubMed  Google Scholar 

  35. •• Morera D, Miller BJ. Meta-analysis of a family history of diabetes in schizophrenia. Schizophr Res. 2024;264:90–4. This study demonstrates that patients with schizophrenia compared with controls have more than a double increase in odds of a family history of T2DM versus controls.

    Article  CAS  PubMed  Google Scholar 

  36. Afzal M, Siddiqi N, Ahmad B, Afsheen N, Aslam F, Ali A, et al. Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:769309.

    Article  PubMed  Google Scholar 

  37. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–47.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Gurpegui M, Martínez-Ortega JM, Gutiérrez-Rojas L, Rivero J, Rojas C, Jurado D. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:169–75.

    Article  PubMed  Google Scholar 

  39. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132:97–108.

    Article  CAS  PubMed  Google Scholar 

  40. Tian Y, Wang D, Wei G, Wang J, Zhou H, Xu H, et al. Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls. Psychopharmacology. 2021;238:745–53.

    Article  CAS  PubMed  Google Scholar 

  41. Bioque M, García-Portilla MP, García-Rizo C, Cabrera B, Lobo A, González-Pinto A, et al. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophr Res. 2018;193:188–96.

    Article  PubMed  Google Scholar 

  42. Gerlach G, Loeber S, Herpertz S. Personality disorders and obesity: a systematic review. Obes Rev. 2016;17:691–723.

    Article  CAS  PubMed  Google Scholar 

  43. Maclean JC, Xu H, French MT, Ettner SL. Personality disorders and body weight. Econ Hum Biol. 2014;12:153–71.

    Article  PubMed  Google Scholar 

  44. •• Wootten JC, Wiener JC, Blanchette PS, Anderson KK. Cancer incidence and stage at diagnosis among people with psychotic disorders: systematic review and meta-analysis. Cancer Epidemiol. 2022;80:102233. This systematic review and meta-analysis found a pooled age-adjusted risk ratio of all cancer slightly higher than in the general population but with important variations according to the specific type of cancer (it also shows an increased risk of metastasis at diagnosis of cancer in schizophrenia subjects).

    Article  PubMed  Google Scholar 

  45. Zhuo C, Tao R, Jiang R, Lin X, Shao M. Cancer mortality in patients with schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2017;211:7–13.

    Article  PubMed  Google Scholar 

  46. Mitchell AJ, Pereira IES, Yadegarfar M, Pepereke S, Mugadza V, Stubbs B. Breast cancer screening in women with mental illness: comparative meta-analysis of mammography uptake. Br J Psychiatry. 2014;205:428–35.

    Article  PubMed  Google Scholar 

  47. Li H, Li J, Yu X, Zheng H, Sun X, Lu Y, et al. The incidence rate of cancer in patients with schizophrenia: a meta-analysis of cohort studies. Schizophr Res. 2018;195:519–28.

    Article  PubMed  Google Scholar 

  48. Ji J, Sundquist K, Ning Y, Kendler KS, Sundquist J, Chen X. Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. Schizophr Bull. 2013;39:527–36.

    Article  PubMed  Google Scholar 

  49. • Zhou K, Zhu L, Chen N, Huang G, Feng G, Wu Q, et al. Causal associations between schizophrenia and cancers risk: a Mendelian randomization study. Front Oncol. 2023;13:1258015. This is the most comprehensive study using Mendelian randomization to explore the causality link between cancer and schizophrenia.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G, et al. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res. 2014;48:102–10.

    Article  PubMed  Google Scholar 

  51. Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234–58.

    Article  PubMed  Google Scholar 

  52. Godin O, Leboyer M, Schürhoff F, Llorca P-M, Boyer L, Andre M, et al. Metabolic syndrome and illness severity predict relapse at 1-year follow-up in schizophrenia: the FACE-SZ cohort. J Clin Psychiatry. 2018;79.

  53. • Godin O, Pignon B, Szoke A, Boyer L, Aouizerate B, Schorr B, et al. 3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort. Prog Neuropsychopharmacol Biol Psychiatry. 2023;120:110641. One of the few existing longitudinal studies of a “real-world” schizophrenia cohort shows a 20.8% incidence in 3 years and identifies several risk factors (i.e. tobacco use, antidepressant).

    Article  CAS  PubMed  Google Scholar 

  54. Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55:29–36.

    Article  PubMed  Google Scholar 

  55. • Hope JD, Keks NA, Copolov DL. Association between long-term use of prolactin-elevating antipsychotics in women and the risk of breast cancer: what are the clinical implications? Australas Psychiatry. 2023;31:205–8, A recent review of the potential role of antipsychotics and prolactin increase in the risk of breast cancer.

    Article  PubMed  PubMed Central  Google Scholar 

  56. De Hert M, Peuskens J, Sabbe T, Mitchell AJ, Stubbs B, Neven P, et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand. 2016;133:5–22.

    Article  PubMed  Google Scholar 

  57. Tang M, Wu X, Zhang W, Cui H, Zhang L, Yan P, et al. Epidemiological and genetic analyses of schizophrenia and breast cancer. Schizophr Bull. 2023;sbad106.

  58. Cui Y, Lu W, Shao T, Zhuo Z, Wang Y, Zhang W. Severe mental illness and the risk of breast cancer: a two-sample, two-step multivariable Mendelian randomization study. PLoS ONE. 2023;18:e0291006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ren F, Shang Q, Zhao S, Yang C, Feng K, Liu J, et al. An exploration of the correlations between seven psychiatric disorders and the risks of breast cancer, breast benign tumors and breast inflammatory diseases: Mendelian randomization analyses. Front Psychiatry. 2023;14:1179562.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Zhang M, Tang J, Li W, Xue K, Wang Z, Chen Y, et al. Schizophrenia mediating the effect of smoking phenotypes on antisocial behavior: a Mendelian randomization analysis. CNS Neurosci Ther. 2023.

  61. Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–95.

    Article  CAS  PubMed  Google Scholar 

  62. Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33:197–207.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Cullen AE, Holmes S, Pollak TA, Blackman G, Joyce DW, Kempton MJ, et al. Associations between non-neurological autoimmune disorders and psychosis: a meta-analysis. Biol Psychiat. 2019;85:35–48.

    Article  PubMed  Google Scholar 

  64. Benros ME, Pedersen MG, Rasmussen H, Eaton WW, Nordentoft M, Mortensen PB. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. AJP. 2014;171:218–26.

    Article  Google Scholar 

  65. de Bartolomeis A, Barone A, Vellucci L, Mazza B, Austin MC, Iasevoli F, et al. Linking inflammation, aberrant glutamate-dopamine interaction, and post-synaptic changes: translational relevance for schizophrenia and antipsychotic treatment: a systematic review. Mol Neurobiol. 2022;59:6460–501.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Torrey EF, Yolken RH. The schizophrenia–rheumatoid arthritis connection: infectious, immune, or both? Brain Behav Immun. 2001;15:401–10.

    Article  CAS  PubMed  Google Scholar 

  67. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry. 2011;168:1303–10.

    Article  PubMed  Google Scholar 

  68. Wang L-Y, Chen S-F, Chiang J-H, Hsu C-Y, Shen Y-C. Autoimmune diseases are associated with an increased risk of schizophrenia: a nationwide population-based cohort study. Schizophr Res. 2018;202:297–302.

    Article  PubMed  Google Scholar 

  69. Chen S-F, Wang L-Y, Chiang J-H, Hsu C-Y, Shen Y-C. Assessing whether the association between rheumatoid arthritis and schizophrenia is bidirectional: a nationwide population-based cohort study. Sci Rep. 2019;9:4493.

    Article  PubMed  PubMed Central  Google Scholar 

  70. • Prados-Ojeda JL, Luque-Luque R, Gordillo-Urbano RM, Guler I, López-Medina C, Collantes-Estévez E, et al. Assessment of subclinical psychotic symptoms in patients with rheumatoid arthritis and spondyloarthritis. J Clin Med. 2021;10:3461. A rare study using sub-clinical psychosis symptoms (psychometric schizotypy) to explore the association with a physical disorder.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Sellgren C, Frisell T, Lichtenstein P, Landèn M, Askling J. The association between schizophrenia and rheumatoid arthritis: a nationwide population-based Swedish study on intraindividual and familial risks. Schizophr Bull. 2014;40:1552–9.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Jeppesen R, Benros ME. Autoimmune diseases and psychotic disorders. Front Psychiatry [Internet]. 2019 [cited 2023 Dec 21];10. Available from: https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00131.

  73. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116:317–33.

    Article  CAS  PubMed  Google Scholar 

  74. McGrath JJ, Saha S, Chant DC, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.

    Article  PubMed  Google Scholar 

  75. Ferentinos P, Dikeos D. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry. 2012;25:381.

    Article  PubMed  Google Scholar 

  76. •• Szöke A, Pignon B, Boster S, Jamain S, Schürhoff F. Schizophrenia: developmental variability interacts with risk factors to cause the disorder: nonspecific variability-enhancing factors combine with specific risk factors to cause schizophrenia. Bioessays. 2020;e2000038. This article introduces the new concept of “variability factors” that might explain (part) of the multimorbidity in conditions with a developmental component.

  77. Szöke A, Pignon B, Schürhoff F. Schizophrenia risk factors in exceptional achievers: a re-analysis of a 60-year-old database. Sci Rep. 2019;9:1294.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B. A role for estrogen in schizophrenia: clinical and preclinical findings. Int J Endocrinol. 2015;2015.

Download references

Acknowledgements

The editors would like to thank Dr. Melvin McInnis for taking the time to review this manuscript.

Author information

Authors and Affiliations

  1. UPEC, Univ Paris Est Creteil, 94000, Créteil, France

    A. Szoke, B. Pignon, O. Godin, A. Ferchiou, R. Tamouza, M. Leboyer & F. Schürhoff

  2. DMU IMPACT Psychiatrie Et Addictologie, Hôpital Albert Chenevier, Pavillon Hartmann, 40, Rue de Mesly, 94000, Créteil, France

    B. Pignon

  3. Fondation Fondamental, 94000, Créteil, France

    A. Szoke, B. Pignon, O. Godin, A. Ferchiou, R. Tamouza, M. Leboyer & F. Schürhoff

Authors
  1. A. Szoke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Pignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Godin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Ferchiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Tamouza
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Leboyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Schürhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Pignon.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Szoke, A., Pignon, B., Godin, O. et al. Multimorbidity and the Etiology of Schizophrenia. Curr Psychiatry Rep 26, 253–263 (2024). https://doi.org/10.1007/s11920-024-01500-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-024-01500-9

Keywords

Search

Navigation